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Transthyretin stabilizera b s t r a c t
Several classes of chemicals are able to bind to the thyroxine binding sites of transthyretin (TTR),
stabilizing its native state and inhibiting in vitro the amyloidogenic process. The amyloidogenic
I84S TTR variant undergoes a large conformational change at moderately acidic pH. Structural evi-
dence has been obtained by X-ray analysis for the native state stabilization of I84S TTR by two chem-
ically distinct ﬁbrillogenesis inhibitors. In fact, they fully prevent the acidic pH-induced protein
conformational change as a result of a long-range stabilizing effect. This study provides further sup-
port to the therapeutic strategy based on the use of TTR stabilizers as anti-amyloidogenic drugs.
Structured summary of protein interactions:
TTR and TTR bind by x-ray crystallography (View interaction)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Protein misfolding and aggregation are involved in the patho-
genesis of particularly important human diseases, the amyloidoses.
Such diseases are characterized by the extracellular deposition of
one of more than 30 amyloidogenic proteins as cross-b-sheet amy-
loid ﬁbrils [1,2]. Speciﬁc mutations may induce or enhance the
amyloidogenic potential of several amyloidogenic proteins, among
which transthyretin (TTR) represents a notable example. Most
mutations in TTR are involved in familial amyloidotic polyneurop-
athy (FAP) and cardiomyopathy (FAC), which are related to the pre-
dominant deposition of ﬁbrillar aggregates of TTR in peripheral
nerves and the heart, respectively [3].TTR is a homotetramer of about 55 kDa involved in the trans-
port of thyroxine (T4) in extracellular ﬂuids, both plasma and cere-
brospinal ﬂuid. The assembly of the four identical subunits in TTR
is highly symmetrical, being characterized by 222 symmetry. Each
monomer is composed of eight antiparallel b-strands, arranged in a
topology similar to that of the Greek key b-barrel, and a short a-he-
lix. Two monomers are held together to form a stable dimer, and
two dimers associate back to back, mainly through a limited num-
ber of hydrophobic contacts, to form the tetramer. A long channel,
at the interface between the two dimers and coincident with one of
the two-fold symmetry axes, transverses the tetrameric protein.
Each symmetric half of the channel harbors a funnel-shaped bind-
ing site for T4.
A large body of evidence has been obtained to indicate that the
rate-limiting dissociation of the native tetrameric state into mono-
mers, followed by misfolding of TTR monomers and their downhill
polymerization, is required to generate protein aggregates in vitro
and presumably in vivo [4, and references therein]. Following these
observations, the properties of a large number of compounds have
been investigated in prospect of their use as drugs effective in the
therapy of TTR amyloidoses [4]. A key feature they must possess is
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Fig. 1. (a) Structural formulae of TTR ligands. (b) Inhibition of ﬁbrillogenesis for I84S TTR at acidic pH. Time-courses of ﬁbril formation for uncomplexed I84S TTR (black) and
in the presence of CHF5074 (red) or diﬂunisal (blue), as determined by monitoring spectrofotometrically the increase in turbidity at 400 nm. In the case of uncomplexed I84S
TTR the ﬁbrillogenesis assay solution contained about 0.5% (v/v) DMSO, as in the case of the assay solutions containing ﬁbrillogenesis inhibitors. See Section 3 for
experimental details. (c) Crystal structure of wt-TTR in complex with CHF5074 at pH 7.0. The ribbon diagram of tetrameric TTR with bound ligand within the two T4 binding
pockets, at the weak dimer–dimer interface, is shown. The close-up view of one binding site depicts the TTR ligand as it is bound in the two symmetry-related binding modes
(yellow and red, stick model). The carboxylate end group of CHF5074 is positioned at the entry port of the T4 binding pocket (outer binding subsite), mimicking the mode of
binding of T4 (forward binding mode). The positions of the two symmetry-related, respectively primed and non-primed, HBPs forming the T4 binding cavity are shown. The
side chains of residues that have at least an atom at a distance shorter than 4 Å from the ligand are shown (stick model). The H-bond interactions of the two Ser117 of
monomers B and B0 with those of monomers A and A0 are explicitly indicated.
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actions with residues of the couple of subunits that line each hor-
mone binding cavity present in the central channel. As a result,
such interactions would bridge neighboring subunits at the di-
mer–dimer interface, thereby stabilizing the TTR tetramer. Indeed,
one such compound, tafamidis, was found to possess quite favor-
able features in vitro and in vivo, such as a highly selective binding
to TTR in human plasma, and was recently approved by EMA (Euro-
pean Medicines Agency) for the treatment of TTR FAP [5].
The crystal structures of amyloidogenic TTR variants are gener-
ally well conserved under native conditions [6]. On the other hand,
structural alterations in the crystal structures of some amyloido-genic TTR variants crystallized at moderately acidic pH (pH 4.6)
[7,8] and of wt-TTR crystallized at pH 4.0 [9] have been revealed.
It should be noted that an acidic pH is also required to promote
in vitro TTR ﬁbrillogenesis, which is mediated by protein destabili-
zation occurring at this pH [10]. Most evident is the alteration
affecting I84S TTR, in which the lowering of the pH (pH 4.6) causes
the unwinding of the TTR short EF-helix (residues 75–82) and the
change in conformation of the adjacent EF-loop hosting the muta-
tion (residues 83–90) in one (B subunit) of the two subunits (A and
B subunits) present in the asymmetric unit [7]. Through the use of
X-ray analyses we show here that the interactions of two chemi-
cally distinct ﬁbrillogenesis inhibitors with I84S TTR prevent the
Table 1
Data collection and reﬁnement statistics.a,b
wt-TTR–CHF5074 complex (pH 7.0) I84S TTR–CHF5074 complex (pH 4.6) I84S TTR–diﬂunisal complex (pH 4.6)
Cell parameters (a, b, c, Å) 42.26, 84.86, 63.95 42.82, 84.66, 65.57 42.80, 86.22, 64.32
Resolutiona (Å) 29.94–1.67 33.01–1.69 32.93–1.69
(1.76–1.67) (1.78–1.69) (1.78–1.69)
Independent reﬂections 27434 (3938) 27449 (3972) 27383 (3948)
Multiplicity 6.7 (6.3) 5.6 (5.6) 6.4 (6.4)
Completeness (%) 99.8 (98.8) 100 (99.9) 99.9 (99.5)
< I/r (I) > 15.1 (4.3) 12.3 (4.5) 16.7 (5.2)
Rmerge
 0.089 (0.386) 0.087 (0.301) 0.060 (0.308)
Reﬁnement
Protein atoms 1785 1795 1795
Water molecules/ligand atoms 197/42 287/42 250/36
Rcryst. (%)/Rfree (%) 0.186/0.229 0.176/0.212 0.192/0.222
r.m.s.d. from ideality
Bond lengths (Å) 0.026 0.009 0.009
Bond angles () 2.2 1.2 1.2
Ramachandran plot:
favored/allowed/disallowed (%) 93/7/0 93/6.5/0.5 91.5/8.5/0
Overall G factor 0.1 0 0.1
 Rmerge ¼ Rhkl jIhklhIhklijRIhkl : Rcryst ¼
Rhkl jjFo jkjFc jj
Rhkl jFo j where |Fo| and |Fc| are the observed and calculated structure factor amplitudes for reﬂection hkl, applied to the work (Rcryst) and test
(Rfree) (5% omitted from reﬁnement) sets, respectively.
a For all crystals the space group is P21212, with a dimer in the asymmetric unit.
b Values in parentheses refer to the outer resolution shell.
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variant.
2. Materials
Recombinant wild type (wt-) and I84S human TTR were pre-
pared and quantiﬁed as described [7]. trans-resveratrol, T4 and
diﬂunisal were from Sigma–Aldrich. CHF5074 was synthesized
according to [11]. Oil B was purchased from Hampton Research
(CA). All chemicals were of analytical grade.
3. Methods
3.1. Inhibition of I84S TTR ﬁbrillogenesis
To highlight the inhibitory effect of diﬂunisal and CHF5074 on
in vitro TTR ﬁbrillogenesis at moderately acidic pH, kinetics of ﬁbril
formation were monitored by following the increase in turbidity,
estimated spectrophotometrically at 400 nm, upon incubation of
I84S TTR or wt-TTR, at ﬁnal concentrations of 3.6 lM, with either
CHF5074 or diﬂunisal, at a ﬁnal concentration of 10.5 lM. Accord-
ing to the procedure adopted for other ﬁbrillogenesis inhibitors
[12], TTR was incubated with ﬁbrillogenesis inhibitors at neutral
pH (10 mM Na phosphate buffer, pH 7, 100 mM KCl, 1 mM EDTA)
for 3 h at room temperature, prior to incubation of the protein at
acidic pH upon addition of an equal volume of 100 mM sodium
acetate, 100 mM KCl, 1 mM EDTA, pH 4.2 (ﬁnal pH 4.3), at 37 C,
in order to promote ﬁbrillogenesis.
3.2. Crystallization
Crystals of ligand–TTR complexes were obtained at room tem-
perature in about one week by cocrystallization, using the hang-
ing-drop vapor diffusion method. Crystals of I84S TTR in complex
with either CHF5074 or diﬂunisal at pH 4.6 were obtained as de-
scribed previously for uncomplexed I84S TTR at acidic pH [7]:
hanging drops containing the TTR variant (5 mg/ml) and a fourfold
molar excess of each ligand were equilibrated against 15% (w/v)
PEG 2000 monomethylether, 0.1 M ammonium sulfate, 0.05 M so-
dium acetate buffer (pH 4.6). Small aliquots of concentrated ligandstock solutions in DMSO were added in cocrystallization experi-
ments (ﬁnal DMSO concentration in the crystal medium upon
equilibration of approx. 4% (v/v)). In a control experiment 4% (v/
v) DMSO was not found to affect signiﬁcantly the ﬁbrillogenesis
kinetics for I84S TTR at acidic pH (Supplemental Fig. S6). To obtain
crystals of wt-TTR in complex with CHF5074 at neutral pH, hang-
ing drops containing wt-TTR (7 mg/ml) and a fourfold molar excess
of CHF5074 were equilibrated against 2 M ammonium sulfate,
0.1 M KCl, 0.05 M sodium phosphate pH 7.0.
3.3. Data collection and structural determination
The datasets concerning the different ligand–TTR complexes
were collected at the synchrotron radiation facility ESRF in Greno-
ble, using beamlines ID23-2 and ID14-eh1. All crystals were brieﬂy
soaked in oil B as a cryoprotectant before freezing and data collec-
tion. Datasets were processed with the software Mosﬂm [13] and
scaled with Scala [14] contained in the CCP4 suite [15]. The struc-
tures of I84S TTR–ligand complexes were reﬁned starting from that
of the dimer of wt-TTR as a template (Protein Data Bank (PDB):
1F41, [6]). The models were subjected to rigid-body minimization
and subsequently to reﬁnement steps with Phenix [16] or Refmac
[17]. Map visualization and manual adjustment of the models were
performed using the Coot graphic interface [18]. Atomic coordi-
nates of the inhibitor molecules and restraints were obtained
through the PRODRG server [19].
4. Results and discussion
4.1. Crystal structures of complexes of ﬁbrillogenesis inhibitors with
wild type and I84S TTR
Two ﬁbrillogenesis inhibitors have been cocrystallized with
TTR: diﬂunisal, a previously characterized ﬁbrillogenesis inhibitor
which is currently being tested in human clinical trials in FAP pa-
tients [20], and CHF5074, a chlorinated derivative of ﬂurbiprofen
[11] (Fig. 1a, Table 1). Fluorometric competitive binding assays,
using resveratrol as ﬂuorescent probe, have shown that CHF5074
possesses high binding afﬁnity for both wt-TTR and I84S TTR (Sup-
plementary data, Figs. S1–S4). Effective inhibitions of ﬁbril forma-
Fig. 2. (a) Stereo view of the electron density map, calculated with coefﬁcients (FobsFcalc) and contoured at 2.5r level only around the ligand, for CHF5074 bound to wt-TTR
at pH 7.0. The two orientations of the ligand, generated by the crystallographic twofold axis, are shown in yellow and orange. (b) Stereo view of the superposition of Ca traces
of I84S TTR at pH 4.6 in complex with CHF5074 (green) and of uncomplexed I84S TTR at the same pH (pale blue). Only the dimer present in the asymmetric unit is shown,
along with one orientation for TTR-bound CHF5074 (C atoms in yellow). It should be noted that the position of residue 84 in monomer B for I84S TTR in complex with
CHF5074 is quite different from that of the same residue present in uncomplexed I84S TTR at pH 4.6 as shown, but superimposes quite well with that of the residue present in
wt-TTR, either uncomplexed or complexed with CHF5074, at pH 7.0. (c) Ribbon representations of the structure of the I84S TTR tetramer at pH 4.6, respectively for the
uncomplexed protein (right side) and for the protein in complex with CHF5074, shown as it is bound inside the T4 binding cavity (left side).
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erately acidic pH have been found for both I84S TTR and wt-TTR
(Fig. 1b and Supplemental Fig. S5, respectively), consistent with
previously reported ﬁbrillogenesis inhibitions of I84S TTR and
wt-TTR by ﬁbrillogenesis inhibitors [12].
In the crystal structures of TTR–CHF5074 complexes the TTR-
bound ligand is relatively well deﬁned for both T4 binding sites
in the TTR tetramer. The inhibitor is bound identically, in the ‘‘for-
ward mode’’, in both wt-TTR cocrystallized at pH 7.0 and I84S TTR
cocrystallized at pH 4.6: the di-chloro phenyl ring is deeply buried
inside the central channel, and the carboxylic moiety protrudes to-
wards the solvent (Fig. 1c). Its electron density, shown in Fig. 2a
and Supplemental Fig. S7 for CHF5074 in complex with wt-TTRat pH 7,0 and I84S TTR at pH 4.6, respectively, was clearly visible
from the ﬁrst stages of reﬁnement. It is well deﬁned for inner
and medium rings, whilst the ligand portion comprising the cyclo-
propane ring and the carboxylate end group is poorly deﬁned, sug-
gesting a rather loose interaction for this ligand moiety (Figs. 2a
and S7). It should be noted, however, that, as in all the other cases
of binding of ligands to the central channel of human TTR, the
molecular (and crystallographic) symmetry of the channel implies
the presence of two possible orientations for the ligand within each
binding site, giving rise to an intrinsic disorder in its electron
density.
The funnel-shaped T4 binding site is characterized by three sub-
sites, each composed of pairs of symmetric halogen binding pock-
G. Zanotti et al. / FEBS Letters 587 (2013) 2325–2331 2329ets (HBPs), wherein the iodine atoms of bound T4 are accommo-
dated: an outer binding subsite (HBP 1 and 10), an inner binding
subsite (HBP 3 and 30), and an intervening interface (HBP 2 and
20), respectively formed by residues Lys15, Leu17, Thr106, and
Val121, residues Ser117, Leu110, Thr119 and Ala108, and residues
Leu17, Ala108, Ala109, Leu110, including the methylene carbons of
Lys15 (PDB: 1ROX, [21]). Both TTR-bound CHF5074 molecules
make hydrophobic and electrostatic interactions with residues lin-
ing the TTR binding cavities. The latter are represented by four po-
lar contacts (Fig. 1c): the carboxylate of CHF5074 is at a close
distance to Lys15 e-NH3+ (2.48–3.15 Å); the para chlorine atom
of the di-chloro phenyl ring is close to the –OH group of Ser117
(Cld–Oc 3.8 Å); the meta chlorine atom interacts with atoms of
the Ser117–Thr118 peptide bond (Cle–O117, 3.36 Å; Cle–N118,
3.71 Å); the ﬂuorine atom interacts with the carbonyl oxygen of
Ala109 (F–O109, 3.52 Å). The Lys15 side chain is held in place by
Glu54 (Oe2–Nf 2.79 Å), which in turn interacts with His56 (Ne2–
Oe1 2.67 Å). The Ser117 side chain is the only one that presents
a different conformation as compared to the apo-protein: its –OH
group is in fact rotated around the Cb–OH bond. Notably, in this
new situation Ser117 and Ser1170 of B and B0 subunits participate
in H-bond interactions with the two Ser117 residues present in A
and A0 subunits (Fig. 1c). The latter interactions between subunits
may thus provide an additional contribution to the stabilization of
tetrameric TTR. Residues making hydrophobic contacts with the li-
gand are Leu17 and Leu170, Ala108 and Ala1080, Leu110, and
Leu1100, Thr119 and Thr1190. A comparison of our structure with
that of TTR in complex with ﬂurbiprofen (Fig. 1 a) (PDB: 1DVT,
[22]) indicates that the most relevant difference between the inter-
actions of the two ligands with TTR is due to the presence of the
two chlorine atoms in CHF5074: they better ﬁll the HBP-3 and
HBP-30 regions, participating in polar interactions.
The situation for I84S TTR in complex with diﬂunisal at acidic
pH is different. Here, the electron density is less deﬁned, suggest-
ing the presence of two orientations (forward and reverse) of the
ligand, in addition to the twofold symmetry, as the cause of disor-
der in the electron density (see PDB: 3D2T [23] for the structure of
wt-TTR in complex with diﬂunisal, which also reveals different ori-
entations for the TTR-bound inhibitor). The Fourier-difference elec-
tron density map for diﬂunisal in complex with I84S TTR at acidic
pH is shown in Supplemental Fig. S8.
4.2. Fibrillogenesis inhibitors protect the native structure of I84S TTR at
acidic pH
We have previously shown that I84S TTR is a conformationally
labile genetic variant, which undergoes a pH-dependent signiﬁcantFig. 3. Ribbon representations of the A–B dimer for I84S TTR at pH 4.6, either in comple
compared to the wt-TTR–CHF5074 complex at pH 7 (center), colored according to the B t
factors).conformational change, characterized by the loss at acidic pH of the
EF-helix and the alteration of the adjacent EF-loop in only one of the
two subunits present in the asymmetric unit [7] (Fig. 2b and c). It
should be pointed out that a large conformational change affecting
the same protein region (residues 75–90) in subunits B was also ob-
served for wt-TTR crystallized at pH 4.0 [9]. However, in this case
the EF-helix slips away from its original position, at variance with
the unfolding of the helix in the case of I84S TTR at pH 4.6. More-
over, a perturbation of the same region was observed for tetrameric
TTR, formed by the association of F87/L110 TTR monomers, in com-
plex with Zn2+ [24]. Regarding the possible cause of the asymmetry
of the conformational change in the tetrameric protein, affecting
only half of the four subunits [7,9], it should be noted that residue
I84 is contiguous with the short a-helix (residues 75–82) and is lo-
cated in the region involved in intermolecular contacts in the crys-
tal lattice. While at neutral pH the four a-helices of I84S TTR are
stable enough to be compatible with their maintenance as in the
case of wt-TTR [7], at pH 4.6 a destabilization of the helices takes
place, so that intermolecular contacts are also affected. In particu-
lar, a new situation selected by crystal lattice would permit the
interaction of an intact a-helix of a subunit of a dimer (the asym-
metric unit) with a loop replacing the a-helix of a subunit of the
symmetry related dimer (PDB: 2G3X, [7]). On the basis of this
hypothesis, one can assume that in solution, in the absence of con-
straints imposed by crystal lattice, the pH-induced conformational
change likely affects all subunits of the I84S TTR tetramer. Themain
aim of this work was to establish whether the presence of two dis-
tinct ﬁbrillogenesis inhibitors, CHF5074 and diﬂunisal, bound in the
T4 binding pockets of TTR could stabilize the native structure of
I84S TTR at acidic pH, permitting the maintenance at low pH of in-
tact intermolecular contacts as for wt-TTR or I84S TTR at neutral
pH. Indeed, the crystal structures of I84S TTR in complex with
CHF5074 or diﬂunisal are very well conserved, even at acidic pH:
the superimposition of the structure of wt-TTR in complex at neu-
tral pH with CHF5074 on the structure of the I84S TTR variant in
complex with CHF5074 or diﬂunisal at acidic pH (pH 4.6) gives
r.m.s.d. between equivalent Ca atoms of 0.34 and 0.29 Å, respec-
tively. The comparison with the structure of uncomplexed wt-TTR
(PDB: 3CFM, [25]) gives a very similar value, 0.38 Å, whilst the same
comparison between the uncomplexed I84S structure at low pH
and the structure of I84S TTR in complex with CHF5074 at low pH
gives values of 0.49 Å for monomers A and 2.12 Å for monomers
B. Therefore, it can be inferred that the bound ﬁbrillogenesis inhib-
itors (either CHF5074 or diﬂunisal) confer a remarkable stability to
the I84S TTR tetramer, as they are able to readjust the altered struc-
ture of uncomplexed I84S TTR at acidic pH, converting it to that typ-
ical of wt-TTR at neutral pH.x with CHF5074 (left side) or as uncomplexed protein (right side, PDB: 2G3X, [7]),
hermal parameters of the main chain, from blue (lowest B factors) to red (highest B
2330 G. Zanotti et al. / FEBS Letters 587 (2013) 2325–2331The analysis of the thermal parameters of the main chain atoms,
illustrated in Fig. 3, for I84S TTR at pH 4.6, either as uncomplexed
protein or in complex with CHF5074, and for wt-TTR at pH 7.0, has
also been performed. In all cases the core of the A–B dimer is quite
rigid in the crystal, whilst most loops are rather ﬂexible, as ex-
pected. In particular, the relatively most ﬂexible parts are loops
36–42 of monomer A and 98–103 of monomer B. The EF-helix
and the adjacent long loop that includes residue 84 are also rigid
or relatively rigid for both monomers A and B in the case of wt-
TTR at pH 7 and of the CHF5074-I84S TTR complex at pH 4.6, whilst
in uncomplexed I84S-TTR at pH 4.6 the latter area becomes very
ﬂexible in monomer B.
Concluding remarks
The ﬁnding that a large protein region (residues 75–90) under-
goes a remarkable conformational change in both I84S TTR at pH
4.6 [7] and wt-TTR at pH 4.0 [9] in two subunits of the TTR tetramer
indicates that it is rather ﬂexible within an otherwise rigid scaffold.
It has been hypothesized that the observed changes in such region
likely destabilize the tetrameric protein and may represent initial
events occurring in the amyloidogenic process [7,9]. In all tested
cases, the structure of TTR in complexwith ﬁbrillogenesis inhibitors
remains nearly unchanged at both neutral and acidic pH, indicating
that the ligand stabilizes the native protein structure mainly by ﬁll-
ing the empty central cavity, withoutmodifying the protein confor-
mation. In particular, the remarkable conformational change we
have observed at pH 4.6 in subunit B for I84S TTR [7], is hampered
by the presence of the ligand. TTR-bound CHF5074 or diﬂunisal
does not establish any speciﬁc interaction with residues of the area
involved in the conformational change: the shortest distance be-
tween the Ca atom of residue 84 and the closest atom of the ligand
is in fact about 20 Å for both monomers (Fig. 2c). We have to con-
clude that the effect of the ligand is not direct, but it must be attrib-
uted to an overall stabilization of the tetramer itself. In particular,
the direct interactions that the two bound ligands establish with
residues of the central channel of TTR appear to have a long-range
effect resulting in the rigidiﬁcation of the tetramer, by reducing the
ﬂexibility of the entire structure and, consequently, the possibility
of transition into the altered conformation induced by amoderately
acidic pH in the I84S TTR variant. It should be noted that two chem-
ically distinct ﬁbrillogenesis inhibitors, such as CHF5074 and diﬂu-
nisal, whose mode of binding to T4 sites of TTR is rather different,
exhibit a quite similar stabilizing effect on TTR structure. This
seems to suggest a commonmechanism of stabilization for ﬁbrillo-
genesis inhibitors. Overall, this study provides direct evidence, on a
structural basis, for the ability of speciﬁc ligands of TTR to preserve
the native structure of this amyloidogenic protein.PDB accession codes
Atomic coordinates and structure factors have been deposited
in the PDB. PDB ID codes are 4I85, 4I87 and 4I89, respectively for
wt-TTR–CHF5074 complex (pH 7.0), I84S TTR–CHF5074 complex
(pH 4.6) and I84S TTR–diﬂunisal complex (pH 4.6).
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